SENN AB Stock Nasdaq Stockholm
Equities
SE0010219626
Biotechnology & Medical Research
Sales 2024 * | 67.55M 6.22M 0 | Sales 2025 * | 91.65M 8.44M 0 | Capitalization | 182M 16.75M 0 |
---|---|---|---|---|---|
Net income 2024 * | -15M -1.38M - | Net income 2025 * | -4M -368K - | EV / Sales 2024 * | 2.57 x |
Net cash position 2024 * | 8M 737K 0 | Net cash position 2025 * | 9M 829K 0 | EV / Sales 2025 * | 1.89 x |
P/E ratio 2024 * |
-12.1
x | P/E ratio 2025 * |
-44.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.56% |
Latest transcript on SENN AB
Managers | Title | Age | Since |
---|---|---|---|
Peter Nählstedt
CEO | Chief Executive Officer | 50 | 17-12-31 |
Marianne Olsson
DFI | Director of Finance/CFO | 63 | 16-10-31 |
Henrik Johansson
CTO | Chief Tech/Sci/R&D Officer | 42 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 76 | 10-08-17 | |
Director/Board Member | 59 | 14-10-14 | |
Paula Zeilon
BRD | Director/Board Member | 62 | 19-12-31 |
1st Jan change | Capi. | |
---|---|---|
-18.16% | 11.13B | |
+58.43% | 3.6B | |
-31.31% | 2.26B | |
-14.31% | 2.16B | |
-26.61% | 1.54B | |
+34.35% | 1.17B | |
-3.28% | 744M | |
-22.75% | 482M | |
-40.20% | 432M |